Search

Your search keyword '"Pouliot, Frédéric"' showing total 481 results
Start Over Author "Pouliot, Frédéric"
481 results on '"Pouliot, Frédéric"'

1. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)

Author

Graham, Jeffrey, Ghosh, Sunita, Breau, Rodney H., Wood, Lori, Tanguay, Simon, Bosse, Dominick, Lalani, Aly-Khan, Bhindi, Bimal, Heng, Daniel, Finelli, Antonio, Fallah-Rad, Nazanin, Castonguay, Vincent, Basappa, Naveen S., Soulières, Denis, Pouliot, Frédéric, Kollmannsberger, Christian, and Bjarnason, Georg A.

Published
2024
Full Text
View/download PDF

2. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Author

Sawaya, Ghady Bou-Nehme, Dragomir, Alice, Wood, Lori A., Kollmannsberger, Christian, Basappa, Naveen S., Kapoor, Anil, Soulières, Denis, Finelli, Antonio, Heng, Daniel Y.C., Castonguay, Vincent, Canil, Christina, Winquist, Eric, Graham, Jeffrey, Bjarnason, Georg A., Bhindi, Bimal, Lalani, Aly-Khan, Pouliot, Frédéric, Breau, Rodney H., Saleh, Ramy, and Tanguay, Simon

Published
2024
Full Text
View/download PDF

5. Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter StudyCONDOR Trial

Author

Morris, Michael J, Rowe, Steven P, Gorin, Michael A, Saperstein, Lawrence, Pouliot, Frédéric, Josephson, David, Wong, Jeffrey YC, Pantel, Austin R, Cho, Steve Y, Gage, Kenneth L, Piert, Morand, Iagaru, Andrei, Pollard, Janet H, Wong, Vivien, Jensen, Jessica, Lin, Tess, Stambler, Nancy, Carroll, Peter R, Siegel, Barry A, and Group, CONDOR Study

Subjects
Clinical Trials and Supportive Activities, Bioengineering, Biomedical Imaging, Cancer, Clinical Research, Prostate Cancer, Urologic Diseases, Adult, Aged, Aged, 80 and over, Humans, Lysine, Male, Middle Aged, Neoplasm Recurrence, Local, Positron Emission Tomography Computed Tomography, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms, Urea, CONDOR Study Group, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeCurrent FDA-approved imaging modalities are inadequate for localizing prostate cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule prostate-specific membrane antigen-targeted PET radiotracer. CONDOR was a prospective study designed to determine the performance of 18F-DCFPyL-PET/CT in patients with BCR and uninformative standard imaging.Experimental designMen with rising PSA ≥0.2 ng/mL after prostatectomy or ≥2 ng/mL above nadir after radiotherapy were eligible. The primary endpoint was correct localization rate (CLR), defined as positive predictive value with an additional requirement of anatomic lesion colocalization between 18F-DCFPyL-PET/CT and a composite standard of truth (SOT). The SOT consisted of, in descending priority (i) histopathology, (ii) subsequent correlative imaging findings, or (iii) post-radiation PSA response. The trial was considered a success if the lower bound of the 95% confidence interval (CI) for CLR exceeded 20% for two of three 18F-DCFPyL-PET/CT readers. Secondary endpoints included change in intended management and safety.ResultsA total of 208 men with a median baseline PSA of 0.8 ng/mL (range: 0.2-98.4 ng/mL) underwent 18F-DCFPyL-PET/CT. The CLR was 84.8%-87.0% (lower bound of 95% CI: 77.8-80.4). A total of 63.9% of evaluable patients had a change in intended management after 18F-DCFPyL-PET/CT. The disease detection rate was 59% to 66% (at least one lesion detected per patient by 18F-DCFPyL-PET/CT by central readers).ConclusionsPerformance of 18F-DCFPyL-PET/CT achieved the study's primary endpoint, demonstrating disease localization in the setting of negative standard imaging and providing clinically meaningful and actionable information. These data further support the utility of 18F-DCFPyL-PET/CT to localize disease in men with recurrent prostate cancer.See related commentary by True and Chen, p. 3512.

Published
2021

6. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).

Author

Pienta, Kenneth J, Gorin, Michael A, Rowe, Steven P, Carroll, Peter R, Pouliot, Frédéric, Probst, Stephan, Saperstein, Lawrence, Preston, Mark A, Alva, Ajjai S, Patnaik, Akash, Durack, Jeremy C, Stambler, Nancy, Lin, Tess, Jensen, Jessica, Wong, Vivien, Siegel, Barry A, and Morris, Michael J

Subjects
Humans, Prostatic Neoplasms, Neoplasm Metastasis, Urea, Prostate-Specific Antigen, Lysine, Prospective Studies, Reproducibility of Results, Aged, Aged, 80 and over, Middle Aged, Male, Positron Emission Tomography Computed Tomography, molecular imaging, neoplasm metastasis, neoplasm staging, prostatic neoplasms, Prevention, Cancer, Clinical Trials and Supportive Activities, Urologic Diseases, Clinical Research, Aging, Prostate Cancer, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Clinical Sciences, Urology & Nephrology
Abstract

PurposeProstate specific membrane antigen-targeted positron emission tomography/computerized tomography has the potential to improve the detection and localization of prostate cancer. OSPREY was a prospective trial designed to determine the diagnostic performance of 18F-DCFPyL-positron emission tomography/computerized tomography for detecting sites of metastatic prostate cancer.Materials and methodsTwo patient populations underwent 18F-DCFPyL-positron emission tomography/computerized tomography. Cohort A enrolled men with high-risk prostate cancer undergoing radical prostatectomy with pelvic lymphadenectomy. Cohort B enrolled patients with suspected recurrent/metastatic prostate cancer on conventional imaging. Three blinded central readers evaluated the 18F-DCFPyL-positron emission tomography/computerized tomography. Diagnostic performance of 18F-DCFPyL-positron emission tomography/computerized tomography was based on imaging results compared to histopathology. In cohort A, detection of pelvic nodal disease (with specificity and sensitivity as co-primary end points) and of extrapelvic metastases were evaluated. In cohort B, sensitivity and positive predictive value for prostate cancer within biopsied lesions were evaluated.ResultsA total of 385 patients were enrolled. In cohort A (252 evaluable patients), 18F-DCFPyL-positron emission tomography/computerized tomography had median specificity of 97.9% (95% CI: 94.5%-99.4%) and median sensitivity of 40.3% (28.1%-52.5%, not meeting prespecified end point) among 3 readers for pelvic nodal involvement; median positive predictive value and negative predictive value were 86.7% (69.7%-95.3%) and 83.2% (78.2%-88.1%), respectively. In cohort B (93 evaluable patients, median prostate specific antigen 11.3 ng/ml), median sensitivity and positive predictive value for extraprostatic lesions were 95.8% (87.8%-99.0%) and 81.9% (73.7%-90.2%), respectively.ConclusionsThe primary end point for specificity was met while the primary end point for sensitivity was not. The high positive predictive value observed in both cohorts indicates that 18F-DCFPyL-positive lesions are likely to represent disease, supporting the potential utility of 18F-DCFPyL-positron emission tomography/computerized tomography to stage men with high-risk prostate cancer for nodal or distant metastases, and reliably detect sites of disease in men with suspected metastatic prostate cancer.

Published
2021

7. External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high‐grade prostate cancer patients

Author

Touma, Nawar, primary, Larose, Maxence, additional, Ouellet, Jade, additional, Bédard‐Tremblay, Daphnée, additional, Singbo, Narcisse, additional, Hovington, Hélène, additional, Neveu, Bertrand, additional, Archambault, Louis, additional, and Pouliot, Frédéric, additional

Published
2024
Full Text
View/download PDF

8. MP07-08 A FULLY AUTOMATED MULTI-TASK MACHINE LEARNING PROGNOSTIC MODEL INTEGRATING RADIOMICS AND CLINICAL DATA TO PREDICT OUTCOMES IN HIGH-GRADE PROSTATE CANCER

Author

Touma, Nawar, primary, Larose, Maxence, additional, Brodeur, Raphaël, additional, Desroches, Félix, additional, Bédard-Tremblay, Daphnée, additional, Raymond, Nicolas, additional, Leblanc, Danahé, additional, Rasekh, Fatemeh, additional, Hovington, Hélène, additional, Neveu, Bertrand, additional, Vallières, Martin, additional, Archambault, Louis, additional, and Pouliot, Frédéric, additional

Published
2024
Full Text
View/download PDF

9. MP07-07 RADIOMICS-BASED PROGNOSTIC MODEL GUIDED BY ARTIFICIAL INTELLIGENCE FOR PREDICTING CLINICAL OUTCOMES IN INDIVIDUALS WITH HIGH-GRADE PROSTATE CANCER

Author

Touma, Nawar, primary, Larose, Maxence, additional, Brodeur, Raphaël, additional, Desroches, Félix, additional, Raymond, Nicolas, additional, Bédard-Tremblay, Daphnée, additional, Leblanc, Danahé, additional, Rasekh, Fatemeh, additional, Hovington, Hélène, additional, Neveu, Bertrand, additional, Vallières, Martin, additional, Archambault, Louis, additional, and Pouliot, Frédéric, additional

Published
2024
Full Text
View/download PDF

10. Screening and management of metabolic, cardiac, and bone health in prostate cancer patients on androgen deprivation therapy

Author

Nguyen, David-Dan, primary, Mousa, Ahmad, additional, Klotz, Laurence, additional, Niazi, Tamim, additional, Pouliot, Frédéric, additional, Kokorovic, Andrea, additional, Lavallée, Luke T., additional, Huynh, Melissa, additional, Lapointe, Nathalie, additional, Di Risio, Michelle, additional, and Wallis, Christopher J.D., additional

Published
2024
Full Text
View/download PDF

11. 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

Author

Chi, Kim N., primary, Yip, Steven M., additional, Bauman, Glenn, additional, Probst, Stephan, additional, Emmenegger, Urban, additional, Kollmannsberger, Christian K., additional, Martineau, Patrick, additional, Niazi, Tamim, additional, Pouliot, Frédéric, additional, Rendon, Ricardo, additional, Hotte, Sebastien J., additional, Laidley, David T., additional, and Saad, Fred, additional

Published
2024
Full Text
View/download PDF

12. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers

Author

Dragomir, Alice, Nazha, Sara, Tanguay, Simon, Breau, Rodney H., Bhindi, Bimal, Rendon, Ricardo A., Kapoor, Anil, Hotte, Sebastien J., Basappa, Naveen, Fairey, Adrian, So, Alan I., Kollmannsberger, Christian, Finelli, Antonio, Hansen, Aaron, Canil, Christina, Heng, Daniel, Lattouf, Jean-Baptiste, Bjarnason, Georg, Power, Nicholas, Pouliot, Frédéric, and Wood, Lori A.

Published
2022
Full Text
View/download PDF

13. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Author

Bedke, Jens, Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dimitry, Pouliot, Frederic, Soulières, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J., Borchiellini, Delphine, McDermott, Raymond S., Tamada, Satoshi, Nguyen, Allison Martin, Wan, Shuyan, Perini, Rodolfo F., Rhoda Molife, L., Atkins, Michael B., and Powles, Thomas

Published
2022
Full Text
View/download PDF

14. Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion

Author

Frégeau-Proulx, Lilianne, Lacouture, Aurélie, Berthiaume, Line, Weidmann, Cindy, Harvey, Mario, Gonthier, Kevin, Pelletier, Jean-François, Neveu, Bertrand, Jobin, Cynthia, Bastien, Dominic, Bergeron, Alain, Fradet, Yves, Lacombe, Louis, Laverdière, Isabelle, Atallah, Chantal, Pouliot, Frédéric, and Audet-Walsh, Étienne

Published
2022
Full Text
View/download PDF

15. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients

Author

Thana, Myuran, Basappa, Naveen S., Ghosh, Sunita, Kollmannsberger, Christian K., Heng, Daniel Y.C., Hansen, Aaron R., Graham, Jeffery, Soulières, Denis, Reaume, Martin Neil, Lalani, Aly-Khan A., Castonguay, Vincent, Bjarnason, Georg A., Patenaude, François, Breau, Rodney H., Pouliot, Frédéric, Kapoor, Anil, and Wood, Lori A.

Published
2022
Full Text
View/download PDF

17. TGFβ Signaling in the Tumor Microenvironment

Author

Goulet, Cassandra Ringuette, Pouliot, Frédéric, Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Xiao, Junjie, Series Editor, and Birbrair, Alexander, editor

Published
2021
Full Text
View/download PDF

19. Addressing controversial areas in the management of advanced prostate cancer in Canada

Author

Saad, Fred, primary, Hotte, Sebastien J., additional, Noonan, Krista, additional, Malone, Shawn, additional, Morash, Christopher, additional, Niazi, Tamim, additional, Rendon, Ricardo A., additional, Shayegan, Bobby, additional, Basappa, Naveen S., additional, Cagiannos, Ilias, additional, Danielson, Brita, additional, Delouya, Guila, additional, Fernandes, Ricardo, additional, Ferrario, Cristiano, additional, Finelli, Antonio, additional, Gotto, Geoffrey T., additional, Hamilton, Robert J., additional, Izard, Jason P., additional, Kapoor, Anil, additional, Lalani, Aly-Khan, additional, Lavallée, Luke T., additional, Ong, Michael, additional, Pouliot, Frédéric, additional, So, Alan I., additional, Yip, Steven, additional, and Chi, Kim N., additional

Published
2023
Full Text
View/download PDF

20. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Author

Sawaya, Ghady Bou-Nehme, primary, Dragomir, Alice, additional, Wood, Lori A., additional, Kollmannsberger, Christian, additional, Basappa, Naveen S., additional, Kapoor, Anil, additional, Soulières, Denis, additional, Finelli, Antonio, additional, Heng, Daniel Y.C., additional, Castonguay, Vincent, additional, Canil, Christina, additional, Winquist, Eric, additional, Graham, Jeffrey, additional, Bjarnason, Georg A., additional, Bhindi, Bimal, additional, Lalani, Aly-Khan, additional, Pouliot, Frédéric, additional, Breau, Rodney H., additional, Saleh, Ramy, additional, and Tanguay, Simon, additional

Published
2023
Full Text
View/download PDF

21. Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens.

Author

Jain, Pallavi, Neveu, Bertrand, Velot, Lauriane, Wu, Lily, Fradet, Yves, and Pouliot, Frédéric

Abstract

Cancer cell heterogeneity is well-documented. Therefore, techniques to monitor single cell heterogeneous responses to treatment are needed. We developed a highly translational and quantitative bioluminescence microscopy method to measure single cell androgen receptor (AR) activity modulation by antiandrogens from fluid biopsies. We showed that this assay can detect heterogeneous cellular response to drug treatment and that the sum of single cell AR activity can mirror the response in the whole cell population. This method may thus be used to monitor heterogeneous dynamic treatment responses in cancer cells.

Published
2016

22. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Author

Powles, Thomas, Plimack, Elizabeth R, Soulières, Denis, Waddell, Tom, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Pouliot, Frédéric, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J, Borchiellini, Delphine, McDermott, Raymond S, Bedke, Jens, Tamada, Satoshi, Yin, Lina, Chen, Mei, Molife, L Rhoda, Atkins, Michael B, and Rini, Brian I

Published
2020
Full Text
View/download PDF

23. An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in Prostate Cancer Cells.

Author

Champagne, Audrey, Chebra, Imene, Jain, Pallavi, Ringuette Goulet, Cassandra, Lauzier, Annie, Guyon, Antoine, Neveu, Bertrand, and Pouliot, Frédéric

Subjects
EXTRACELLULAR matrix, BIOLUMINESCENCE, PROSTATE cancer, ANDROGEN receptors, ANTIANDROGENS, CELL culture
Abstract

Prostate cancer (PCa) displays diverse intra-tumoral traits, impacting its progression and treatment outcomes. This study aimed to refine PCa cell culture conditions for dynamic monitoring of androgen receptor (AR) activity at the single-cell level. We introduced an extracellular matrix-Matrigel (ECM-M) culture model, enhancing cellular tracking during bioluminescence single-cell imaging while improving cell viability. ECM-M notably tripled the traceability of poorly adherent PCa cells, facilitating robust single-cell tracking, without impeding substrate permeability or AR response. This model effectively monitored AR modulation by antiandrogens across various PCa cell lines. Single-cell imaging unveiled heterogeneous antiandrogen responses within populations, correlating non-responsive cell proportions with drug IC50 values. Integrating ECM-M culture with the PSEBC-TSTA biosensor enabled precise characterization of ARi responsiveness within diverse cell populations. Our ECM-M model stands as a promising tool to assess heterogeneous single-cell treatment responses in cancer, offering insights to link drug responses to intracellular signaling dynamics. This approach enhances our comprehension of the nuanced and dynamic nature of PCa treatment responses. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice.

Author

Chi, Kim N., Yip, Steven M., Bauman, Glenn, Probst, Stephan, Emmenegger, Urban, Kollmannsberger, Christian K., Martineau, Patrick, Niazi, Tamim, Pouliot, Frédéric, Rendon, Ricardo, Hotte, Sebastien J., Laidley, David T., and Saad, Fred

Subjects
CASTRATION-resistant prostate cancer, ANDROGEN receptors, ADVERSE health care events
Abstract

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant prostate cancer (mCRPC). As this treatment represents a new therapeutic class, guidance regarding how to integrate it into clinical practice is needed. This article aims to review the evidence from prospective phase 2 and 3 clinical trials and meta-analyses of observational studies on the use of 177Lu-PSMA-617 in prostate cancer and discuss how Canadian clinicians might best apply these data in practice. The selection of appropriate patients, the practicalities of treatment administration, including necessary facilities for treatment procedures, the assessment of treatment response, and the management of adverse events are considered. Survival benefits were observed in clinical trials of 177Lu-PSMA-617 in patients with progressive, PSMA-positive mCRPC who were pretreated with androgen receptor pathway inhibitors and taxanes, as well as in taxane-naïve patients. However, the results of ongoing trials are awaited to clarify questions regarding the optimal sequencing of 177Lu-PSMA-617 with other therapies, as well as the implications of predictive biomarkers, personalized dosimetry, and combinations with other therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer

Author

Neveu, Bertrand, Jain, Pallavi, Têtu, Bernard, Wu, Lily, Fradet, Yves, and Pouliot, Frédéric

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Genetics, Prevention, Cancer, Biomedical Imaging, Urologic Diseases, Aging, Biotechnology, Prostate Cancer, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Aged, Aged, 80 and over, Androgens, Animals, Antigens, Neoplasm, Cell Line, Cell Line, Tumor, Dihydrotestosterone, Gene Amplification, Gene Expression Regulation, Neoplastic, Hep G2 Cells, Humans, Male, Mice, SCID, Middle Aged, Models, Genetic, Promoter Regions, Genetic, Prostate, Prostatic Neoplasms, Sensitivity and Specificity, Transcriptional Activation, Transplantation, Heterologous, prostate cancer, PCA3, vector system and targeting strategies, non-invasive imaging in animal, Oncology and carcinogenesis
Abstract

Targeting specifically primary prostate cancer (PCa) cells for immune therapy, gene therapy or molecular imaging is of high importance. The PCA3 long non-coding RNA is a unique PCa biomarker and oncogene that has been widely studied. This gene has been mainly exploited as an accurate diagnostic urine biomarker for PCa detection. In this study, the PCA3 promoter was introduced into a new transcriptional amplification system named the 3-Step Transcriptional Amplification System (PCA3-3STA) and cloned into type 5 adenovirus. PCA3-3STA activity was highly specific for PCa cells, ranging between 98.7- and 108.0-fold higher than that for benign primary prostate epithelial or non-PCa cells, respectively. In human PCa xenografts, PCA3-3STA displayed robust bioluminescent signals at levels that are sufficient to translate to positron emission tomography (PET)-based reporter imaging. Remarkably, when freshly isolated benign or cancerous prostate biopsies were infected with PCA3-3STA, the optical signal produced from primary PCa biopsies was significantly higher than from benign prostate biopsies (4.4-fold, p < 0.0001). PCA3-3STA therefore represents a PCa-specific expression system with the potential to target, with high accuracy, primary or metastatic PCa epithelial cells for imaging, vaccines, or gene therapy.

Published
2016

27. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

Author

Plimack, Elizabeth R., primary, Powles, Thomas, additional, Stus, Viktor, additional, Gafanov, Rustem, additional, Nosov, Dmitry, additional, Waddell, Tom, additional, Alekseev, Boris, additional, Pouliot, Frédéric, additional, Melichar, Bohuslav, additional, Soulières, Denis, additional, Borchiellini, Delphine, additional, McDermott, Raymond S., additional, Vynnychenko, Ihor, additional, Chang, Yen-Hwa, additional, Tamada, Satoshi, additional, Atkins, Michael B., additional, Li, Chenxiang, additional, Perini, Rodolfo, additional, Molife, L. Rhoda, additional, Bedke, Jens, additional, and Rini, Brian I., additional

Published
2023
Full Text
View/download PDF

28. The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors at Canadian academic centers

Author

Lemire, Francis, primary, Zhang, MengQi, additional, Anderson, Patrick, additional, Finelli, Antonio, additional, Rendon, Ricardo A., additional, Tanguay, Simon, additional, Bansal, Rahul, additional, Bhindi, Bimal, additional, So, Alan I., additional, Pouliot, Frédéric, additional, Dean, Lucas, additional, Mallick, Ranjeeta, additional, Lavallée, Luke T., additional, and Breau, Rodney H., additional

Published
2023
Full Text
View/download PDF

29. Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial

Author

Savard, Josée, primary, Moussa, Hanane, additional, Pelletier, Jean‐François, additional, Julien, Pierre, additional, Lacombe, Louis, additional, Tiguert, Rabi, additional, Caumartin, Yves, additional, Dujardin, Thierry, additional, Toren, Paul, additional, Pouliot, Frédéric, additional, Lodde, Michele, additional, Fradet, Yves, additional, Robitaille, Karine, additional, and Fradet, Vincent, additional

Published
2023
Full Text
View/download PDF

30. Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)]

Author

Plimack, Elizabeth R., primary, Powles, Thomas, additional, Stus, Viktor, additional, Gafanov, Rustem, additional, Nosov, Dmitry, additional, Waddell, Tom, additional, Alekseev, Boris, additional, Pouliot, Frédéric, additional, Melichar, Bohuslav, additional, Soulières, Denis, additional, Borchiellini, Delphine, additional, McDermott, Raymond S., additional, Vynnychenko, Ihor, additional, Chang, Yen-Hwa, additional, Tamada, Satoshi, additional, Atkins, Michael B., additional, Li, Chenxiang, additional, Perini, Rodolfo, additional, Rhoda Molife, L., additional, Bedke, Jens, additional, and Rini, Brian I., additional

Published
2023
Full Text
View/download PDF

32. Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8–10 Prostate Cancers Identifies Very High–risk Patients for Early Recurrence and Resistance to Castration

Author

Lavallée, Etienne, Bergeron, Michelle, Buteau, François-Alexandre, Blouin, Annie-Claude, Duchesnay, Nicolas, Dujardin, Thierry, Tiguert, Rabi, Lacombe, Louis, Fradet, Vincent, Makao-Nguile, Molière, Fradet, Yves, Beauregard, Jean-Mathieu, and Pouliot, Frédéric

Published
2019
Full Text
View/download PDF

35. Estimated glomerular filtration rate from the renal hypothermia trial: clinical implications

Author

Lemire, Francis, primary, Fergusson, Dean A., additional, Knoll, Greg, additional, Morash, Christopher, additional, Lavallée, Luke T., additional, Mallick, Ranjeeta, additional, Finelli, Antonio, additional, Kapoor, Anil, additional, Pouliot, Frédéric, additional, Izawa, Jonathan, additional, Rendon, Ricardo, additional, Cagiannos, Ilias, additional, and Breau, Rodney H., additional

Published
2023
Full Text
View/download PDF

36. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer

Author

Gonthier, Kevin, primary, Weidmann, Cindy, additional, Berthiaume, Line, additional, Jobin, Cynthia, additional, Lacouture, Aurélie, additional, Lafront, Camille, additional, Harvey, Mario, additional, Neveu, Bertrand, additional, Loehr, Jérémy, additional, Bergeron, Alain, additional, Fradet, Yves, additional, Lacombe, Louis, additional, Riopel, Julie, additional, Latulippe, Éva, additional, Atallah, Chantal, additional, Shum, Michael, additional, Lambert, Jean‐Philippe, additional, Pouliot, Frédéric, additional, Pelletier, Martin, additional, and Audet‐Walsh, Étienne, additional

Published
2023
Full Text
View/download PDF

37. Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial

Author

Tremblay, Samuel, primary, Alhogbani, Mofarej, additional, Weickhardt, Andrew, additional, Davis, Ian D, additional, Scott, Andrew M, additional, Hicks, Rodney J, additional, Metser, Ur, additional, Chua, Sue, additional, Davda, Reena, additional, Punwani, Shonit, additional, Payne, Heather, additional, Tunariu, Nina, additional, Ho, Bao, additional, Young, Sympascho, additional, Singbo, Mahukpe Narcisse Ulrich, additional, Bauman, Glenn, additional, Emmett, Louise, additional, and Pouliot, Frédéric, additional

Published
2023
Full Text
View/download PDF

38. Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC)

Author

Lavallée, Luke T., Fitzpatrick, Ryan, Wood, Lori A., Basiuk, Joan, Knee, Christopher, Cnossen, Sonya, Mallick, Ranjeeta, Witiuk, Kelsey, Vanhuyse, Marie, Tanguay, Simon, Finelli, Antonio, Jewett, Michael A. S., Basappa, Naveen, Lattouf, Jean-Baptiste, Gotto, Geoffrey T., Al-Asaaed, Sohaib, Bjarnason, Georg A., Moore, Ronald, North, Scott, Canil, Christina, Pouliot, Frédéric, Soulières, Denis, Castonguay, Vincent, Kassouf, Wassim, Cagiannos, Ilias, Morash, Chris, and Breau, Rodney H.

Published
2019
Full Text
View/download PDF

41. Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population

Author

Millan, Braden, primary, Breau, Rodney H., additional, Mallick, Ranjeeta, additional, Wood, Lori, additional, Rendon, Ricardo, additional, Finelli, Antonio, additional, So, Alan I., additional, Lavallée, Luke T., additional, Pouliot, Frédéric, additional, Bhindi, Bimal, additional, Heng, Daniel, additional, Drachenberg, Darrel, additional, Tanguay, Simon, additional, Dean, Lucas, additional, Basappa, Naveen S., additional, Lattouf, Jean-Baptiste, additional, Bjarnason, George, additional, Lalani, Aly-Khan, additional, and Kapoor, Anil, additional

Published
2023
Full Text
View/download PDF

42. Abstract 3700: Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle in prostate cancer

Author

Gonthier, Kevin, primary, Weidmann, Cindy, additional, Berthiaume, Line, additional, Jobin, Cynthia, additional, Lacouture, Aurélie, additional, Lafront, Camille, additional, Harvey, Mario, additional, Neveu, Bertrand, additional, Loehr, Jérémy, additional, Bergeron, Alain, additional, Fradet, Yves, additional, Lacombe, Louis, additional, Riopel, Julie, additional, Latulippe, Éva, additional, Atallah, Chantal, additional, Shum, Michael, additional, Lambert, Jean-Philippe, additional, Pouliot, Frédéric, additional, Pelletier, Martin, additional, and Audet-Walsh, Étienne, additional

Published
2023
Full Text
View/download PDF

44. Table S3 from Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non–Muscle-Invasive Bladder Cancer: A Gene–Smoking Interaction

Author

Lacombe, Louis, primary, Fradet, Vincent, primary, Lévesque, Éric, primary, Pouliot, Frédéric, primary, Larue, Hélène, primary, Bergeron, Alain, primary, Hovington, Hélène, primary, Caron, André, primary, Nguile-Makao, Molière, primary, Harvey, Mario, primary, Fradet, Yves, primary, and Guillemette, Chantal, primary

Published
2023
Full Text
View/download PDF

46. Data from Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non–Muscle-Invasive Bladder Cancer: A Gene–Smoking Interaction

Author

Lacombe, Louis, primary, Fradet, Vincent, primary, Lévesque, Éric, primary, Pouliot, Frédéric, primary, Larue, Hélène, primary, Bergeron, Alain, primary, Hovington, Hélène, primary, Caron, André, primary, Nguile-Makao, Molière, primary, Harvey, Mario, primary, Fradet, Yves, primary, and Guillemette, Chantal, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Appendix from Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

Author

Morris, Michael J., primary, Rowe, Steven P., primary, Gorin, Michael A., primary, Saperstein, Lawrence, primary, Pouliot, Frédéric, primary, Josephson, David, primary, Wong, Jeffrey Y.C., primary, Pantel, Austin R., primary, Cho, Steve Y., primary, Gage, Kenneth L., primary, Piert, Morand, primary, Iagaru, Andrei, primary, Pollard, Janet H., primary, Wong, Vivien, primary, Jensen, Jessica, primary, Lin, Tess, primary, Stambler, Nancy, primary, Carroll, Peter R., primary, and Siegel, Barry A., primary

Published
2023
Full Text
View/download PDF

48. Figure S1 from Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

Author

Morris, Michael J., primary, Rowe, Steven P., primary, Gorin, Michael A., primary, Saperstein, Lawrence, primary, Pouliot, Frédéric, primary, Josephson, David, primary, Wong, Jeffrey Y.C., primary, Pantel, Austin R., primary, Cho, Steve Y., primary, Gage, Kenneth L., primary, Piert, Morand, primary, Iagaru, Andrei, primary, Pollard, Janet H., primary, Wong, Vivien, primary, Jensen, Jessica, primary, Lin, Tess, primary, Stambler, Nancy, primary, Carroll, Peter R., primary, and Siegel, Barry A., primary

Published
2023
Full Text
View/download PDF

50. UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways

Author

Lacombe, Louis, primary, Hovington, Hélène, additional, Brisson, Hervé, additional, Mehdi, Sadia, additional, Beillevaire, Déborah, additional, Émond, Jean-Philippe, additional, Wagner, Antoine, additional, Villeneuve, Lyne, additional, Simonyan, David, additional, Ouellet, Véronique, additional, Barrès, Véronique, additional, Latour, Mathieu, additional, Aprikian, Armen, additional, Bergeron, Alain, additional, Castonguay, Vincent, additional, Couture, Félix, additional, Chevalier, Simone, additional, Brimo, Fadi, additional, Fazli, Ladan, additional, Fleshner, Neil, additional, Gleave, Martin, additional, Karakiewicz, Pierre I., additional, Lattouf, Jean-Baptiste, additional, Trudel, Dominique, additional, van der Kwast, Theodorus, additional, Mes-Masson, Anne-Marie, additional, Pouliot, Frédéric, additional, Fradet, Yves, additional, Audet-Walsh, Etienne, additional, Saad, Fred, additional, Guillemette, Chantal, additional, and Lévesque, Eric, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results